{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-283008","form_type":"8-K","ticker":"BMEA","cik":"0001840439","company_name":"Biomea Fusion, Inc.","filed_at":"2024-12-20T23:59:59+00:00","discovered_at":"2026-05-14T18:03:09.968172+00:00","generated_at":"2026-05-29T00:29:22.056276+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Biomea Fusion icovamenib Phase II meets primary endpoint; 1.47% HbA1c reduction in insulin-deficient T2D patients","bullets":["Best response in beta-cell deficient patients on antidiabetic agents: placebo-adjusted HbA1c reduction 1.47% at Week 26 (p=0.022) after 12 weeks dosing.","Arm B (100mg QD for 12 weeks) showed mean HbA1c reduction of 0.5% (p=0.012) in per protocol patients on one or more baseline therapy.","In insulin-deficient subtypes (SIDD/MARD), Arm B demonstrated mean HbA1c reduction of 1.05% (p=0.004).","Icovamenib well-tolerated: no AE-related discontinuations, no hypoglycemic events, no related serious adverse events.","Company plans to discuss data with FDA; 52-week readout anticipated in H2 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-283008","json":"https://secwatch.observer/filing/0001193125-24-283008.json","markdown":"https://secwatch.observer/filing/0001193125-24-283008.md","text":"https://secwatch.observer/filing/0001193125-24-283008.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1840439/000119312524283008/0001193125-24-283008-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1840439/000119312524283008/d827448d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-29T00:29:22.056276+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}